The role of SSRIs in panic disorder

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 10, 1996, Pages 51-60

  Sheehan, David V ^a   Harnett Sheehan, Kathy ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; NEFAZODONE; PAROXETINE; RITANSERIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIAZOLOPYRIDAZINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

ANTICHOLINERGIC EFFECT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERANCE; HAMILTON SCALE; HUMAN; META ANALYSIS; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

1-NAPHTHYLAMINE; CITALOPRAM; CLINICAL TRIALS; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; HUMANS; PANIC DISORDER; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0029835841     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Klein DF, Fink M. Psychiatry reaction patterns to imipramine. Am J Psychiatry 1962;119:432-438
2. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408
3. Klein DF. The importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967;16:118-126
4. Modigh K. Antidepressant drugs in anxiety disorders. Acta Psychiatr Scand 1987;16:118-126
5. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
6. Klerman GL. Treatments for panic disorder. J Clin Psychiatry 1992;53(3, suppl):14-19
7. Asberg M, Bertillsson L, Martensson B, et al. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-219
8. Coppen AJ, Doognan DP. Serotonin and its place in the pathogenesis of depression. J Clin Psychiatry 1988;49(8, suppl):4-11
9. Heninger GR, Charney DS, Steinberg DE. Serotonergic function in depression: prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry 1984;41:398-402
10. Shapira B, Reiss A, Kaiser N, et al. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Disord 1989;16:1-4
11. Sheehan DV, Zak JP, Miller JA, et al. Panic disorder; the potential role of serotonin reuptake inhibitors. J Clin Psychiatry 1988;49(8, suppl):30-36
12. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety, II: effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24
13. Kahn R, Asnis C, Wetzler S, et al. Neuroendocrine evidence for a serotonin receptor supersensitivity in panic disorder. Psychopharmacology (Berl) 1988;96:360-364
14. Kahn R, Wetzler S, Van Praag HM, et al. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 1988;25:101-104
15. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306
16. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(6, suppl):4-10; Correction, 1991;52:353
17. Berney T, Kolvin I, Bhate SR, et al. School phobia: a therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry 1981;138:110-118
18. Pecknold JC, McClure DJ, Appeltauer L, et al. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br J Psychiatry 1982;140:484-490
19. Modigh K, Westenberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261
20. Kahn RS, Westenberg HGM, Verhoeven WMA, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine, and placebo. Int Clin Psychopharmacol 1987;2:33-45
21. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453-459
22. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder, I: clomipramine and lofepramine in DSM-IH-R panic disorder: a placebo-controlled trial. J Affect Disord 1992;25:63-75
23. Den Boer JA, Westenberg HG, Kamerbeek WOJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
24. Gentil V, Lotufoneto F, Andrade L, et al. Clomipramine, a better reference drug for panic/agoraphobia: effectiveness comparison with imipramine. J Psychopharmacol 1993;7:316-324
25. Cassano GB, Petracca A, Perugi G, et al. Clomipramine for panic disorder, I: the first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988;14:123-127
26. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;2(16, suppl): 577-582
27. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res 1977;(suppl 5):116-123
28. Gloger S, Grunhaus L, Birmacher B, et al. Treatment of spontaneous panic attacks with clomipramine. Am J Psychiatry 1981;138:1215-1217
29. Westenberg HGM, Den Boer JA. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol Bull 1989;25:119-123
30. Den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double-blind, placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94
31. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
32. Bakish D, Filteau MJ, Charbonneau Y, et al. A double-blind, placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Presented at the Collegium Internationale Neuro-Psychopharmacologicum regional workshop "Current Therapeutical Approaches in Panic and Other Anxiety Disorders," November 20-22, 1993; Monte Carlo. Neuropsychopharmacology 1994;10: 35(Part 2)1150:27-39
33. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-326
34. Sharp DM, Power KG, Simpson RJ, et al. Fluvoxamine, placebo and cognitive behavior therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord 1996;10(4):219-242
35. Asnis GM. Effects of fluvoxamine on the treatment of panic disorder: a placebo-controlled trial. An Psiquiatria (Madrid) 1992;8(suppl 1):78
36. Den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74
37. Van Vliet IM. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Developments in the Neurobiology and Psychopharmacology of Panic Disorder and Social Phobia, pg 120-133. Utrecht, The Netherlands: University of Utrecht, Netherlands; 1996. Dissertation
38. Den Boer JA, Van Vliet IM, Westenberg HGM. A double-blind comparative study of fluvoxamine and brofaromine in panic disorder. Clin Neuropharmacol 1992;15(suppl 1, pt B):91B(Abs-65-176)
39. Servant D, Bailly D, Parquet PHJ. Fluvoxamine in the treatment of panic disorder with obsessive compulsive symptoms [letter]. Am J Psychiatry 1988;145:1174-1175
40. Servant D, Bailly D, Le Seach H, et al. Obsessive compulsive symptoms associated with panic disorder: predictive factor of a good therapeutic response to fluvoxamine. Encephale 1990; July-August; 16 (spec No.): 359-362
41. Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-332
42. Schneier F, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121
43. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-438
44. Du Boff E, England D, Ferguson JM, et al. Sertraline in the treatment of panic disorder [Abstract]. Presented at the VIIIth Congress of the European College of Neuropsychopharmacology; September 30-October 4, 1995; Venice, Italy
45. Gorman J, Wolkow R. Sertraline as a treatment for panic disorder. Neuropsychopharmacology 1994;10:35-197S
46. Johnson AM. The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feighner JP, Boyer EF, eds. Selective Serotonin Reuptake Inhibitors. New York, NY: Wiley; 1991:37-70
47. Lecrubier Y (on behalf of the Panic Disorder Study Group). A double-blind, placebo-controlled study of paroxetine and clomipramine in the treatment of panic disorder. Poster presented at the 7th Congress of the Association of European Psychiatrists, September 18-24, 1994; Copenhagen, Denmark
48. Dunbar G, Judge R, on behalf of the Panic Disorder Study Group. A double-blind, placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. Poster presented at the VIIIth Congress of the European College of Neuropsychopharmacology; September 30-October 4, 1995; Venice, Italy
49. Dunbar G, Judge R, Morton N. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Poster presented at the VIIIth Congress of the European College of Neuropsychopharmacology; September 30-October 4, 1995; Venice, Italy
50. Oehrberg S, Christiansen PE, Behnke K, et al, Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
51. Steiner M, Oakes R, Gergel IP, et al. A fixed dose study of paroxetine and placebo in the treatment of panic disorder. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla. Abstract NR355:150
52. Dunbar G, Steiner M, Oakes R, et al. A fixed dose study of paroxetine and placebo in the treatment of panic disorder. Poster presented at the VIIIth Congress of the European College of Neuropsychopharmacology; September 30-October 4, 1995; Venice, Italy
53. Sheehan DV, Dunbar G (on behalf of the Panic Disorder Study Group). The treatment of panic disorder with paroxetine. In: Gotestam KG, Mindus P, Sheehan DV, eds. Proceedings of the Second Novo Nordisk Symposium on Panic Disorder and OCD. The Netherlands: Medical Forum International; 1996:29-38
54. Burnham DB, Steiner MX, Gergel IP, et al. Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Presented in a poster session at the American College of Neuropsychopharmacology; 1995; San Juan, Puerto Rico
55. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(suppl 5):21-39
56. Wade AG. The optimal therapeutical area for SSRIs: panic disorder [abstract]. Presented at the VIIIth Congress of the European College of Neuropsychopharmacology; September 30-October 4, 1995; Venice, Italy
57. Dassylva B, Fontaine R, Gammans D, et al. Efficacy of nefazodone in patients suffering from major depressive disorder and panic disorder [abstract]. Biol Psychiatry 1992;31:169A
58. Koczkas S, Holmberg G, Wedin L. A pilot study of the effect of the 5-HT-uptake inhibitor, zimelidine, on phobic anxiety. Acta Psychiatr Scand 1981;63:328-341
59. Evans L, Kenardy J, Schneider P, et al. Effect of a selective serotonin reuptake inhibitor in agoraphobia with panic attacks: a double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand 1986;73: 49-53
60. Evans L, Bert J, Moore G, et al. Zimelidine: a serotonin uptake Hocker in the treatment of phobic anxiety. Prog Neuropsychopharmacology 1980;4: 75-79
61. Evans L, Moore G. The treatment of phobic anxiety by zimelidine. Acta Psychiatr Scand 1981;63:342-345
62. Koczkas S. Zimelidine treatment in phobias: a placebo-controlled study with a selective 5-HT reuptake inhibitor. Poster presented at the VIIth World Congress of Psychiatry; July 12, 1983; Vienna, Austria
63. Mavissakalian M, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987;144:785-787
64. Charney DS, Woods WS, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-586
65. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49